Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report)’s stock price hit a new 52-week low during trading on Tuesday . The stock traded as low as $2.80 and last traded at $2.8150, with a volume of 2991418 shares trading hands. The stock had previously closed at $2.89.
Wall Street Analysts Forecast Growth
RXRX has been the subject of several analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. JPMorgan Chase & Co. cut their target price on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Morgan Stanley boosted their price target on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research report on Thursday, May 14th. Wall Street Zen lowered Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $8.10.
Get Our Latest Stock Analysis on RXRX
Recursion Pharmaceuticals Stock Up 3.9%
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. The firm had revenue of $6.47 million during the quarter, compared to the consensus estimate of $15.78 million. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The firm’s revenue for the quarter was down 56.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.50) earnings per share. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.02 EPS for the current year.
Insider Activity
In other Recursion Pharmaceuticals news, CEO Najat Khan sold 28,298 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $3.35, for a total value of $94,798.30. Following the completion of the sale, the chief executive officer directly owned 2,262,085 shares of the company’s stock, valued at approximately $7,577,984.75. This represents a 1.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Ben R. Taylor sold 7,956 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $3.39, for a total transaction of $26,970.84. Following the transaction, the chief financial officer owned 1,180,318 shares of the company’s stock, valued at approximately $4,001,278.02. This trade represents a 0.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 96,254 shares of company stock worth $320,369 over the last 90 days. 8.43% of the stock is currently owned by company insiders.
Institutional Trading of Recursion Pharmaceuticals
Several institutional investors and hedge funds have recently added to or reduced their stakes in RXRX. International Assets Investment Management LLC acquired a new position in Recursion Pharmaceuticals in the fourth quarter worth approximately $31,000. Integral Investment Advisors Inc. acquired a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at $39,000. Sequoia Financial Advisors LLC bought a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth $41,000. MQS Management LLC bought a new stake in shares of Recursion Pharmaceuticals during the 1st quarter worth $41,000. Finally, Allworth Financial LP grew its holdings in shares of Recursion Pharmaceuticals by 85.6% in the 3rd quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock worth $47,000 after acquiring an additional 4,403 shares during the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.
At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.
Read More
- Five stocks we like better than Recursion Pharmaceuticals
- Corpay’s Quiet Strength Is Winning Wall Street
- Investors Abandoned These 3 AI Stocks Too Early, Says Jeff Clark
- Freight Boom: The Hormuz Blockade Payday
- The Palantir Paradox—Record Numbers and a Stock That Won’t Cooperate
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
